X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trastuzumab Duocarmazine
Therapeutic Area: Oncology Product Name: SYD985
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The Phase III TULIP study “SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer” met its primary endpoint of progression-free survival, demonstrating a statistically significant improvement over physician’s choice.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Trastuzumab duocarmazine
Therapeutic Area: Oncology Product Name: SYD985
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Syneos Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 16, 2020
Details:
Byondis is drafting plans to pursue commercialisation partners for when results from its Phase III breast cancer antibody-drug conjugate study are released in 2Q21.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): (vic-) trastuzumab duocarmazine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2020
Details:
Byondis is expecting results from its pivotal TULIP® Phase III trial comparing SYD985 to physician's choice treatment in patients with HER2-positive metastatic breast cancer.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
